1.Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction.
Kun ZHANG ; Xin-chao ZHANG ; Yu-hong MI ; Juan LIU
Chinese Medical Journal 2013;126(19):3628-3631
BACKGROUNDAcute myocardial infarction (AMI) is a common cardiac emergency with high mortality. Serum soluble ST2 (sST2) is a new emerging biomarker of cardiac diseases. The present study is to investigate the predictive value of sST2 and interleukin-33 (IL-33) for risk stratification and prognosis in patients with AMI.
METHODSFifty-nine patients with AMI, whose chief complaint was chest pain or dyspnea, were selected for our study. Physical examination, chest radiograph, electrocardiograph (ECG), biomarkers of myocardial infarction, NT-proBNP, echocardiography and other relevant examinations were performed to confirm the diagnosis of AMI. Thirty-six healthy people were chosen as the control group. Serum samples from these subjects (patients within 24 hours after acute attack) were collected and the levels of sST2 and IL-33 were assayed by enzyme-linked immuno-sorbent assay (ELISA) kit. The follow-up was performed on the 7th day, 28th day, 3rd month and 6th month after acute attack. According to the follow-up results we defined the end of observation as recurrence of AMI or any causes of death.
RESULTSMedian sST2 level of the control group was 9.38 ng/ml and that of AMI patients was 29.06 ng/ml. Compared with the control group, sST2 expression in the AMI group was significantly different (P < 0.001). In contrast, the IL-33 level showed no significant difference between the two groups. Serum sST2 was a predictive factor independent of other variables and may provide complementary information to NT-proBNP or GRACE risk score. IL-33 had no relationship to recurrence of AMI. Both sST2 and the IL-33/sST2 ratio were correlated with the 6-month prognosis; areas under the ROC curve were 0.938 and 0.920 respectively.
CONCLUSIONSEarly in the course (<24 hours) of AMI, sST2 usually increases markedly. The increase of sST2 has an independent predictive value for the prognosis in AMI patients and provides complementary information to NT-proBNP or GRACE risk score. The IL-33/sST2 ratio correlates with the 6-month prognosis of AMI patients. However, there is no significant relationship between IL-33 and the prognosis of AMI patients.
Acute Disease ; Biomarkers ; blood ; Female ; Humans ; Interleukin-1 Receptor-Like 1 Protein ; Interleukin-33 ; Interleukins ; blood ; Male ; Myocardial Infarction ; blood ; Natriuretic Peptide, Brain ; blood ; Peptide Fragments ; blood ; Prognosis ; Receptors, Cell Surface ; blood ; Risk
2.Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis.
Hyun Suk YANG ; Mina HUR ; Hanah KIM ; Laura MAGRINI ; Rossella MARINO ; Salvatore DI SOMMA
Annals of Laboratory Medicine 2016;36(6):590-594
Soluble suppression of tumorigenicity 2 (sST2) has emerged as a biomarker of cardiac stretch or remodeling, and has demonstrated a role in acutely decompensated heart failure. However, its role in sepsis-induced cardiac dysfunction is still unknown. We explored whether sST2 serum concentration reflects either systolic or diastolic dysfunction as measured by Doppler echocardiography. In a total of 127 patients with sepsis, correlations between sST2 and blood pressure, left ventricular (LV) ejection fraction, LV diastolic filling (ratio of early transmitral flow velocity to early diastolic mitral annulus velocity), and resting pulmonary arterial pressure were evaluated. Correlations between sST2 and other sepsis biomarkers (high-sensitivity C-reactive protein [hs-CRP] and procalcitonin) were also examined. sST2 showed a moderate correlation with mean arterial pressure (r=-0.3499) but no correlation with LV ejection fraction, diastolic filling, or resting pulmonary hypertension. It showed moderate correlations with hs-CRP and procalcitonin (r=0.2608 and r=0.3829, respectively). sST2 might have a role as a biomarker of shock or inflammation, but it cannot reflect echocardiographic findings of LV ejection fraction or diastolic filling in sepsis.
Aged
;
Aged, 80 and over
;
Biomarkers/blood
;
Blood Pressure/physiology
;
C-Reactive Protein/analysis
;
Calcitonin/blood
;
Echocardiography, Doppler
;
Female
;
Humans
;
Interleukin-1 Receptor-Like 1 Protein/*blood
;
Male
;
Middle Aged
;
Sepsis/diagnostic imaging/metabolism/*physiopathology
;
Ventricular Function, Left/physiology
3.Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction.
Wei-Ping HUANG ; Xuan ZHENG ; Lei HE ; Xi SU ; Cheng-Wei LIU ; Ming-Xiang WU
Chinese Medical Journal 2018;131(11):1282-1288
BackgroundSerum soluble ST2 (sST2) levels are elevated early after acute myocardial infarction and are related to adverse left ventricular (LV) remodeling and cardiovascular outcomes in ST-segment elevation myocardial infarction (STEMI). Beta-blockers (BB) have been shown to improve LV remodeling and survival. However, the relationship between sST2, final therapeutic BB dose, and cardiovascular outcomes in STEMI patients remains unknown.
MethodsA total of 186 STEMI patients were enrolled at the Wuhan Asia Heart Hospital between January 2015 and June 2015. All patients received standard treatment and were followed up for 1 year. Serum sST2 was measured at baseline. Patients were divided into four groups according to their baseline sST2 values (high >56 ng/ml vs. low ≤56 ng/ml) and final therapeutic BB dose (high ≥47.5 mg/d vs. low <47.5 mg/d). Cox regression analyses were performed to determine whether sST2 and BB were independent risk factors for cardiovascular events in STEMI.
ResultsBaseline sST2 levels were positively correlated with heart rate (r = 0.327, P = 0.002), Killip class (r = 0.408, P = 0.000), lg N-terminal prohormone B-type natriuretic peptide (r = 0.467, P = 0.000), lg troponin I (r = 0.331, P = 0.000), and lg C-reactive protein (r = 0.307, P = 0.000) and negatively correlated to systolic blood pressure (r = -0.243, P = 0.009) and LV ejection fraction (r = -0.402, P = 0.000). Patients with higher baseline sST2 concentrations who were not titrated to high-dose BB therapy (P < 0.0001) had worse outcomes. Baseline high sST2 (hazard ratio [HR]: 2.653; 95% confidence interval [CI]: 1.201-8.929; P = 0.041) and final low BB dosage (HR: 1.904; 95% CI, 1.084-3.053; P = 0.035) were independent predictors of cardiovascular events in STEMI.
ConclusionsHigh baseline sST2 levels and final low BB dosage predicted cardiovascular events in STEMI. Hence, sST2 may be a useful biomarker in cardiac pathophysiology.
Adrenergic beta-Antagonists ; administration & dosage ; therapeutic use ; Adult ; Aged ; Biomarkers ; blood ; Female ; Humans ; Interleukin-1 Receptor-Like 1 Protein ; blood ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; ST Elevation Myocardial Infarction ; blood ; drug therapy ; pathology
4.Soluble ST2 Has a Prognostic Role in Patients With Suspected Sepsis.
Mina HUR ; Hanah KIM ; Hyun Jeong KIM ; Hyun Suk YANG ; Laura MAGRINI ; Rossella MARINO ; Patrizia CARDELLI ; Salvatore DI SOMMA
Annals of Laboratory Medicine 2015;35(6):570-577
BACKGROUND: Soluble suppression of tumorigenicity 2 (sST2) has emerged as a novel biomarker for heart failure, and serum sST2 concentrations could be increased in inflammatory diseases. We explored whether sST2 is related to cardiac dysfunction/failure and has a prognostic role in patients with suspected sepsis. METHODS: In a total of 397 patients with suspected sepsis, sST2 concentrations were measured by using the Presage ST2 Assay (Critical Diagnostics, USA). sST2 concentrations were analyzed according to procalcitonin (PCT) concentrations, cardiovascular subscores of the sepsis-related organ failure assessment (SOFA) score, and clinical outcomes. RESULTS: sST2 concentrations were increased significantly according to the five groups of PCT concentrations and cardiovascular subscores of the SOFA score (P<0.000001 and P=0.036, respectively). In-hospital mortality was significantly higher among patients with sST2 concentrations above 35 ng/mL (P=0.0213) and among patients with increased concentrations of both sST2 and PCT (P=0.0028). CONCLUSIONS: sST2 seems to be related to both cardiac dysfunction/failure and severity in sepsis. Measurement of sST2 and PCT in combination would be useful for risk stratification and prognosis prediction in patients with suspected sepsis.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Biomarkers/blood
;
Calcitonin/blood
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Hospital Mortality
;
Humans
;
Interleukin-1 Receptor-Like 1 Protein/*blood
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Prognosis
;
Proportional Hazards Models
;
Reagent Kits, Diagnostic
;
Sepsis/*diagnosis/mortality/pathology
;
Young Adult
5.Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome.
Vera CELIC ; Anka MAJSTOROVIC ; Biljana PENCIC-POPOVIC ; Aleksandra SLJIVIC ; Natalia LOPEZ-ANDRES ; Ignacio ROY ; Elena ESCRIBANO ; Maite BEUNZA ; Amaia MELERO ; Federico FLORIDI ; Laura MAGRINI ; Rossella MARINO ; Gerardo SALERNO ; Patrizia CARDELLI ; Salvatore DI SOMMA
Annals of Laboratory Medicine 2016;36(6):542-549
BACKGROUND: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS. METHODS: A multicentric, cross-sectional study was conducted on180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay. RESULTS: LV mass index (β=0.337, P<0.001, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, P=0.048, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, P=0.05, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD. CONCLUSIONS: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.
Adult
;
Age Factors
;
Aged
;
Area Under Curve
;
Blood Pressure
;
Body Mass Index
;
Cross-Sectional Studies
;
Echocardiography, Doppler
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Hypertrophy, Left Ventricular/diagnostic imaging
;
Interleukin-1 Receptor-Like 1 Protein/*analysis
;
Linear Models
;
Logistic Models
;
Male
;
Metabolic Syndrome X/metabolism/*physiopathology
;
Middle Aged
;
ROC Curve
;
Sex Factors
;
Ventricular Function, Left/*physiology
;
Ventricular Remodeling/physiology